Clinical use of the prostate-specific antigen (PSA) test dramatically improved the screening sensitivity of prostate cancer compared to that of traditional methods; in turn, the number of patients with early-stage prostate cancer has rapidly increased since the mid-1990s [15, 16]. The gene discussed is KLK3; the disease is prostate cancer.